KB16A

N/A

Report date: 2025/04/29 09:25:32

Base Information

Drug NameKB16A
Drug Alias NameKB-16-AKB16A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionLeukocyte immunoglobulin-like receptor subfamily B member 2 inhibitors
TargetsLeukocyte immunoglobulin-like receptor subfamily B member 2
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited Kingdom
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesKBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesKBio Inc
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A